GR1803 injection Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

Genrix (Shanghai) Biopharmaceutical Co., Ltd.3

Indications

Multiple Myeloma2
Cancer2
Auto Immune Disease1
Systemic Lupus Erthematosus1
Lupus1

Other3 trials

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

A Study of GR1803 in Systemic Lupus Erythematosus

Phase 1/2

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.